CSP
4 min read
21

Recalculation of warrants of series TO5 in Wyld Networks AB

November 11, 2024
0

Reading Time: 3 minutes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF

Continue Reading
CSP
1 min read
19

#24-388 Delisting of Derivatives from NGM

November 11, 2024
0

Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
12

#24-387 Listing of Derivatives at NGM

November 11, 2024
0

Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
16

Orkla ASA: Mandatory notification of trade – options

November 11, 2024
0

Reading Time: < 1 minute Reference is made to the previous stock exchange release on 31 October 2024 regarding exercise of share options by primary insider Christer Grönberg under Orkla ASA’s long term share incentive programme. The sales process conducted by a third party is

Continue Reading
CSP
1 min read
16

Wärtsilä President & CEO Håkan Agnevall on sick leave until 25 November

November 11, 2024
0

Reading Time: < 1 minute Wärtsilä Corporation, Stock exchange release, 11 November 2024 at 17.00 EET Wärtsilä President & CEO Håkan Agnevall on sick leave until 25 November Wärtsilä’s President & CEO Håkan Agnevall will be on sick leave due to a planned routine surgery

Continue Reading
Vedanta Ltd. Reports Highest-Ever 1H EBITDA at .47 Billion
BWI
3 min read
32

Vedanta Ltd. Reports Highest-Ever 1H EBITDA at $2.47 Billion

November 11, 2024
0

Reading Time: 2 minutes Indian multinational, Vedanta Limited (“Vedanta”) (NSE: VEDL), world’s leading critical and future minerals, energy and technology conglomerate announced its results for Q2 and H1 ending September 30, 2024. It reported highest-ever 1H EBITDA at $2.47 billion, up 46% YoY1. The company’s Q2 consolidated revenue was $4.4

Continue Reading
Megaport Launches in Brazil, Bringing Industry-Leading Global Network to South America
BWI
3 min read
22

Megaport Launches in Brazil, Bringing Industry-Leading Global Network to South America

November 11, 2024
0

Reading Time: 3 minutes Brisbane, Australia:   Megaport Limited (ASX: MP1) (“Megaport”), the global leading Network as a Service (NaaS) provider, announces its official expansion into Brazil, establishing its connectivity services in São Paulo. This expansion enables enterprises to securely connect locally and globally between 860+

Continue Reading
CSP
5 min read
11

Norconsult ASA: Settlement of Employee Share Program 2023 (“Gift Shares”)

November 11, 2024
0

Reading Time: 4 minutes Sandvika, 11 November 2024 (OSE: NORCO): Reference is made to the announcement by Norconsult ASA (the “Company”) regarding the Employee Share Program (the “Share Program”) described in the announcement from 10 November 2023 in connection with the Company’s first day of

Continue Reading
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
BWI
4 min read
29

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

November 11, 2024
0

Reading Time: 3 minutes Beijing, China & South San Francisco, Calif., United States:   IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen’s potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034) This milestone further validates Biocytogen’s proprietary RenLite® antibody

Continue Reading
What Trends Determine iGaming in 2025? Insights from SOFTSWISS Report
CSP
3 min read
16

What Trends Determine iGaming in 2025? Insights from SOFTSWISS Report

November 11, 2024
0

Reading Time: 3 minutes What technologies reshape the future of iGaming? Which business models will ensure growth for the companies? SOFTSWISS, a leading tech company with over 15 years of experience in iGaming, shares its much anticipated new iGaming Trends 2025 Report. The new edition

Continue Reading